Liver-targeted chemo shows promise for tough bile duct cancer

NCT ID NCT03364530

Recruiting now Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests giving chemotherapy drugs (gemcitabine and oxaliplatin) directly into the liver's main artery for people with advanced bile duct cancer that hasn't spread elsewhere. The goal is to shrink tumors while reducing side effects. About 40 adults who have already tried one standard treatment will receive this therapy. The main measure of success is whether tumors shrink at least 30% after 4 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine and oxaliplatin chemotherapy
What this could lead to: If successful, this could offer a new second-line treatment option to shrink liver tumors in patients with advanced bile duct cancer that hasn't spread.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The treatment involves invasive catheter placement and carries risks like infection or liver damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA NON-RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLANGIOCARCINOMA NON-RESECTABLE NON-METASTATIC

Contacts and locations

Locations

Amiens University Hospital
RECRUITING

Amiens, France
Angers University Hospital
RECRUITING

Angers, France
Bordeaux University Hospital
RECRUITING

Bordeaux, France
Centre Georges François Leclerc
RECRUITING

Dijon, France
Hôpital Européen Georges Pompidou
RECRUITING

Paris, France
Institut Gustave Roussy
RECRUITING

Villejuif, France
Uhmontpellier
RECRUITING

Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.